LabPMM® of Invivoscribe® has introduced the KMT2A MRD Testing Service on a global basis to facilitate the development of menin inhibitors. Treatment of acute leukemias. This very sensitive digital PCR-based service can be helpful for health professionals, clinical investigators, & biopharmaceutical firms for tracking molecular disease changes. The KMT2A MRD Testing Service can be accessed from the laboratory facilities of LabPMM® internationally.
New KMT2A Minimal Residual Disease Testing Service caters to the increasing need for molecular testing in patients suffering from acute leukemia. Rearrangements of KMT2A (KMT2Ar) represent important cancer-causing alterations in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
This translocation is observed in almost 80% of infant leukemia patients. The translocation is also observed in 5-15% of leukemia cases among children and adults. In addition, KMT2A rearrangement leukemia is associated with chemoresistance, high risks of relapse, and difficult clinical management.
However, the advent of the menin inhibitors has brought about a shift in the treatment approach for AML & ALL patients. This treatment is particularly important in patients suffering from KMT2A-rearranged and NPM1-mutated cancers. The FDA approved the first menin inhibitor for relapsed or refractory acute leukemia with KMT2A translocation. This approval validated the treatment class.
Advancing Molecular Monitoring for Acute Leukemia Treatment
With menin inhibitors expanding into frontline and combination clinical trials, there is a need for dependable molecular test solutions. Thus, LabPMM’s KMT2A MRD Testing Service will help detect alterations in KMT2Ar, evaluate molecular response, and monitor treatment efficacy.
“Menin inhibitors are creating important new possibilities for patients with KMT2A-rearranged leukemia, but continued development requires a partner that can deliver highly sensitive, standardized molecular data across clinical programs and geographies,” said Jeff Miller, CEO and CSO of Invivoscribe. “By making KMT2A MRD testing available through LabPMM, we are helping clinicians and biopharmaceutical partners measure meaningful responses earlier, monitor their durability, and ultimately improve patient care.”
The LabPMM test targets common KMT2A fusion partner genes prevalent in both AML and ALL. The test is quantitative as it measures KMT2Ar relative to a housekeeping gene. The test is important for disease evaluation and MRD monitoring and has high sensitivity levels of up to 0.005%. Moreover, the test provides results within 48 hours. This launch improves the molecular testing portfolio of Invivoscribe. The Invivoscribe molecular testing portfolio includes standardized tests for FLT3, NPM1, KMT2A screening, MRD monitoring, & AML assessment by flow cytometry.
The combination of Invivoscribe and LabPMM forms an ecosystem worldwide that consists of MRD testing, regulatory compliance, and diagnostics. Consequently, such services allow scientists to assess treatment efficiency, select patients, and facilitate clinical trial decisions. It allows for a consistent collection of molecular data at all levels, from development to marketing authorization.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
